Skip to main content
SpringerLink
Log in

Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

An Erratum to this article was published on 31 March 2015

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Maxson JE, Gotlib J, Pollyea DA et al (2013) Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 368:1781–1790

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  2. Fleischman AG, Maxson JE, Luty SB et al (2013) Blood 122:3628–3631

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Piazza R, Valletta S, Winkelmann N et al (2013) Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 45:18–24

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  4. Lasho TL, Mims A, Elliott MA et al (2014) Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib. Leukemia 28:1363–1365

    Article  CAS  PubMed  Google Scholar 

  5. Dao KH, Solti MB, Maxson JE et al (2014) Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. Leukemia Res Rep 3:67–69

    Article  Google Scholar 

  6. Pardanani A, Lasho TL, Laborde RR et al (2013) CSF3RT618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 27:1870–1873

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  7. Wang SA, Hasserjian RP, Fox PS et al (2014) Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123:2645–2651

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Hematology, Erasmus University Medical Center, Cancer Institute Daniel den Hoed, Groene Hilledijk 301, 3075, Rotterdam, The Netherlands

    Emanuele Ammatuna, Matthias Eefting, Kirsten van Lom, François F. Kavelaars, Peter J. M. Valk & Ivo P. Touw

Authors
  1. Emanuele Ammatuna
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthias Eefting
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kirsten van Lom
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. François F. Kavelaars
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Peter J. M. Valk
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ivo P. Touw
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emanuele Ammatuna.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ammatuna, E., Eefting, M., van Lom, K. et al. Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. Ann Hematol 94, 879–880 (2015). https://doi.org/10.1007/s00277-014-2272-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-014-2272-0

Keywords

Search

Navigation